Therapeutic | Sifalimumab |
Target | IFNA1 |
Heavy Chain | QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYSISWVRQAPGQGLEWMGWISVYNGNTNYAQKFQGRVTMTTDTSTSTAYLELRSLRSDDTAVYYCARDPIAAGYWGQGTLVTVSS |
Light Chain | EIVLTQSPGTLSLSPGERATLSCRASQSVSSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRTFGQGTKVEIK |
100% seqID Fv Structure | 4ypg [Fvs: BA, HL] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 4ypg [Fvs: BA, HL] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-II |
Estimated Status (June '19) | Discontinued |
Recorded Developmental Technology | na |
INN Year Proposed | 2009 |
INN Year Recommended | 2010 |
Companies Involved | Medarex, MedImmune |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | Myositis, Psoriasis, Systemic lupus erythematosus |
Notes |